Cystic fibrosis, Pseudomonas aeruginosa, and selective decontamination

A Mark Dalzell, Hendrik K F van Saene, David P Heaf

Abstract
We used an oral topical antibiotic preparation to try and prevent oropharyngeal carriage of Pseudomonas aeruginosa in patients with cystic fibrosis. Ten of 15 patients treated with a two week course of intravenous ceftazidime together with a 90 day course of an antibiotic containing gel continued to carry P aeruginosa in the oropharynx.

The technique of selective decontamination of the digestive system uses oral antibiotic combinations to prevent the overgrowth of certain groups of organism (typically Gram negative aerobes), and allows the more usual flora to maintain colonisation resistance. It has application particularly in the immunocompromised patient undergoing cytotoxic chemotherapy and in long term ventilated patients, where Gram

negative aerobes normally confined to the large bowel may colonise first the oropharynx and then the lower respiratory tract.

The principle of selective decontamination has been previously adopted in cystic fibrosis patients carrying *Pseudomonas aeruginosa* when using antipseudomonal agents delivered by aerosol. Although this treatment has been successful in reducing the number of pseudomonas isolates, and in reducing the frequency of lower respiratory tract exacerbations, it has proved impossible to eradicate *P. aeruginosa*. This pilot study was conducted in order to find out whether an oral topical antibiotic preparation could prevent oropharyngeal carriage.

Subjects and methods

The study group comprised cystic fibrosis patients from whom *P. aeruginosa* was isolated for the first time in consecutive oropharyngeal samples during a period of two weeks. All patients took flucloxacinil as prophylaxis against staphylococcal colonisation of the respiratory tract.

Patients were admitted to hospital regardless of clinical condition, and treated initially with intravenous cefazidime (150 mg/kg/day) for 14 days. In addition a selective decontamination gel composed of a 2% mixture of polymyxin E, tobramycin, and amphotericin B in a 3:5% carboxymethyl cellulose base was applied topically to the buccal mucosa and gingiva four times a day after meals. On completion of the initial inpatient stay a further 76 days of oral gel application was completed at home.

Respiratory tract infections (both upper and lower) during the period of the study were treated on merit. Upper respiratory coryzal illness was treated with an additional oral antibiotic either amoxyccillin, erythromycin, or trimethoprim, and lower respiratory infections unresponsive to the above antibiotics were treated with oral ciprofloxacin, nebulised aminoglycoside, or intravenous cefazidime.

**Bacteriological Monitoring**

Weekly throat and rectal swabs, together with lower airway samples, were cultured prospectively throughout and subsequent to the treatment period. All samples were cultured both qualitatively and quantitatively.

**Quantitative culture**

An aliquot of 1 ml or 1 g of specimen was suspended in a sterile culture tube containing 9 ml of brain heart infusion (BHI, broth, No 49, Lab M). All specimens were serially diluted (1:10 steps), subcultured onto solid media using the four quadrant method, and the tip of the swab was broken off into broth. The concentrations of micro-organisms were estimated on a scale of 1+ to 5+. If only broth was positive, the growth density was recorded as 1+ (according to $\leq 10^1$ colony forming units (cfu)/ml or g); macroscopic growth in the first quadrant scored 2+ (according to $\leq 10^2$ cfu/ml or g) etc.

**Qualitative culture**

Morphologically distinct colonies were isolated in pure culture and identified by standard procedures (analytical profile index 20 E, coagulase, etc). Antibiotic sensitivities were determined using a controlled disc diffusion method for each of the different isolates. The antibacterial agents used for flora suppression (polymyxin E, tobramycin) and for systemic treatment (ceftazidime) were tested.

**Definitions**

Oropharyngeal carriage was defined as the presence of identical pseudomonas species in any concentration in at least two consecutive throat swabs over a period of two weeks.

Infection of the upper respiratory tract was a clinical diagnosis based on rhinorrhoea and cough thought to be viral in origin in most cases. Infection of the lower airways was a microbiologically proved clinical diagnosis with the sample yielding $10^6$ cfu/ml or more.

The effectivenss of the topical antimicrobial gel during this study was judged by the eradication and/or prevention of *P. aeruginosa* carriage in the oropharynx. In addition, Fisher's exact test and Student's t test were used to compare respiratory exacerbations, the use of additional antibiotics, and weight gain during the study period and for the subsequent 90 days.

**Results**

Fifteen children (nine boys and six girls) with cystic fibrosis, mean age 7.5 years (18 months–15.6 years) were assessed. Three patients failed

---

**Table 1 Clinical details of cystic fibrosis patients**

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age at diagnosis (months)</th>
<th>Shwachman score when colonised</th>
<th>Age at which <em>P. aeruginosa</em> colonised (months)</th>
<th>Continued <em>P. aeruginosa</em> isolation during selective decontamination period</th>
<th><em>P. aeruginosa</em> isolation three months after selective decontamination period</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>65</td>
<td>89</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>17</td>
<td>75</td>
<td>69</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>60</td>
<td>178</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>30</td>
<td>60</td>
<td>153</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>6</td>
<td>75</td>
<td>10</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>90</td>
<td>111</td>
<td></td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>2</td>
<td>90</td>
<td>52</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>27</td>
<td>95</td>
<td>137</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>3</td>
<td>85</td>
<td>24</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>10</td>
<td>18</td>
<td>60</td>
<td>23</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>11</td>
<td>24</td>
<td>55</td>
<td>92</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>12</td>
<td>48</td>
<td>85</td>
<td>64</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>
to complete the study: one did not fulfill the entry criteria and two patients did not like applying the oral gel. Clinical details of the 12 patients who completed the study are shown in Table 1.

Ten patients (83%) continued to yield *P aeruginosa* from the throat and sputum during the treatment period and from the oropharynx during the three months after completion of the study (p=0.3). *P aeruginosa* was intermittently cultured from rectal swabs taken from three patients during the study period.

Table 2 shows clinical data for the selective decontamination period and the subsequent 90 days. There was no detectable benefit to the patient during the selective decontamination period in terms of weight gain or reduced frequency of respiratory exacerbations.

Discussion

Together with *Staphylococcus aureus* and *Haemophilus influenzae, P aeruginosa* is the commonest isolate from the oropharynx of patients with cystic fibrosis. Sporadic isolates of *P aeruginosa* are not unusual in patients with cystic fibrosis, but once oropharyngeal carriage has occurred, eradication is rare. The application of an oral selective decontamination gel was of no benefit to 10 out of 12 patients in preventing carriage of *P aeruginosa* within the oropharynx. The organism ultimately colonises most patients and has at least two strategies to facilitate survival. Once established in the respiratory tract, mucoid variants are commonly found. The 'slime' probably protects colonies from host defences, and intramural proteins have been identified in *P aeruginosa*, which may protect against antibiotic attack. *Pseudomonas* is not an oropharyngeal commensal, nor is it cultured from stool unless a large inoculum (10^6) is ingested orally. Even then, in normal individuals colonisation of the bowel does not occur.3 Three patients were identified as having pseudomonal colonisation of the bowel because of repeated isolates from rectal swabs during attempted oral selective decontamination.

The failure of a selective decontamination approach in cystic fibrosis may be due to a number of factors. Lindemann et al found that the oropharynx is a reservoir for the organism which may colonise by virtue of its preferred attachment to altered epithelial surfaces in the oropharynx of cystic fibrosis patients.5 In contrast to the success achieved in ventilated patients where an antibiotic containing paste has been effective,6 it was necessary to use an antibiotic containing gel because of the unpalatability of paste. The mucosal contact time of the gel compared with paste may have reduced antibiotic effectiveness. The reasons why patients with cystic fibrosis are colonised by *P aeruginosa* are still unclear, and the difficulties encountered in trying to prevent carriage of the organism remain.

Nocturnal faecal soiling and anal masturbation

A F Clark, P J Tayler, S R Bhate

Abstract

Two cases of late onset faecal soiling as a result of anal masturbation in children who were neither mentally handicapped nor psychopathic were studied. The role of soiling in aiding the young person and his family to avoid separating and maturing is highlighted. We suggest that the association of anal masturbation and resistant nocturnal soiling may be unrecognised.

Faecal soiling is defined as disordered bowel function and control occurring in children over